PCC-0208027

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NamePCC-0208027
Drug Alias NamePCC-0208027
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor protein-tyrosine kinase erbB-4 inhibitors
TargetsReceptor protein-tyrosine kinase erbB-2Epidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-4
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShenyang Pharmaceutical University
China Registration ClassN/A

Develop Information

Active CompaniesShenyang Pharmaceutical University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A